BioSpace News Archive

Ironwood Pharmaceuticals, Inc., a GI-focused healthcare company, announced positive topline results from its pivotal Phase III STARS trial, which evaluated the efficacy and safety of once-weekly subcutaneous apraglutide in reducing parenteral support dependency in adult patients with short bowel syndrome with intestinal failure.

DENTSPLY SIRONA Inc. announced that Eric K. Brandt, who has served as a Director on the Company’s Board of Directors for nearly twenty years and as Chairman of the Board for six years, has informed the Board of his intention to retire at the May 2024 annual meeting and that he will not be standing for re-election.

Immunic, Inc. today announced the presentation of data from the company’s phase 2 CALLIPER and CALVID-1 clinical trials of lead asset, nuclear receptor related 1 (Nurr1) activator, vidofludimus calcium (IMU-838), in two poster presentations at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2024, taking place from February 29 to March 2, in West Palm Beach, FL.

Vapotherm, Inc., a global medical technology company specializing in the development and commercialization of its proprietary Vapotherm high-velocity therapy® products for patients of all ages experiencing respiratory distress, is pleased to announce the regulatory approval of the HVT 2.0 system in Brazil.

ANI Pharmaceuticals, Inc. announced financial results and business highlights for the fourth quarter and full year ended December 31, 2023.

Amarin Corporation plc, announced financial results for the quarter and year ended December 31, 2023 and provided an update on the Company’s operations.

Chimerix reported financial results for the fourth quarter and full-year ended December 31, 2023 and provided an operational update.

Emergent BioSolutions Inc. will host a conference call on Wednesday, March 6, 2024, at 5:00 pm eastern time to discuss the financial results for the fourth quarter and full year 2023.

SN Bioscience Co. Ltd. announced on Feb 27 that the US FDA had granted an orphan drug designation for pancreatic cancer for SNB-101, a new polymer nanoparticle drug under development, based on the pre-clinical data of SNB-101 on pancreatic cancer animal model.

Genethon, a non-profit research organization focused on developing gene therapies for rare diseases, marks International Rare Disease Day by highlighting its efforts to bring gene therapies to patients suffering from rare diseases such as limb girdle muscular dystrophies, Crigler Najjar syndrome and Duchenne muscular dystrophy.